Healthcare
Live Price
Offline$9.05
-1.09% today
Window Change
+0.55%
Window
Apr 17, 2026 โ Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 40 bars ยท Apr 17, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alpine Immune Sciences, Inc. (ALPN) is a Healthcare stock with a market cap of $4.46B. The stock last traded around $9.05 and up 0.5% across the available one-year price window (Apr 17, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +95.8%, EPS growth of +63.0%, a dividend yield of 0.0%. What stands out right now is revenue +95.8%, EPS +63.0%, free cash flow -80.0% with operating margin -75.2% and ROIC -13.1%. Valuation already assumes a fairly strong business story at price/sales 75.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ALPN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+95.8% vs +7.6% peer median
Operating Margin
Below sector median
-75.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2024 was reported on May 9, 2024 with an EPS surprise of +34.9% and a revenue surprise of +101.5%.
The operating story is still moving forward
Revenue is running at +95.8% and EPS at +63.0%, with operating margin around -75.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2024 May 9, 2024 | +34.9% | -1.1% | +0.0% | +2.2% |
2024 Mar 18, 2024 | +135.3% | -1.1% | +0.0% | +2.2% |
2023 Nov 14, 2023 | +31.4% | -1.1% | +0.0% | +2.2% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ALPN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ALPN Max Drawdown
-7.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for ALPN and SPY.
Company Overview
Alpine Immune Sciences, Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.